Core Viewpoint - Inhibrx Biosciences, Inc. announced positive primary results from the ChonDRAgon clinical study evaluating ozekibart (INBRX-109) for advanced or metastatic, unresectable chondrosarcoma patients, leading to plans for a U.S. regulatory submission by June 2026 [1] Group 1: Clinical Study Results - The ChonDRAgon study involved 206 participants and demonstrated significant improvement in progression-free survival (PFS) for chondrosarcoma patients treated with ozekibart compared to placebo [1] - Ozekibart is the first investigational drug to show a significant improvement in PFS in a randomized controlled trial for this patient population [1] Group 2: Regulatory and Commercial Plans - Inhibrx plans to submit a marketing application for ozekibart for chondrosarcoma to U.S. regulatory authorities by the end of June 2026 [1] - The company holds exclusive development and commercialization rights for ozekibart in mainland China, Hong Kong, Macau, and Taiwan through a licensing agreement with its wholly-owned subsidiary, HJB [1] Group 3: Market Implications - The encouraging clinical data reinforces the value of ozekibart for global patients and in regions where the company has exclusive rights [1] - Currently, there are no approved systemic treatment options for chondrosarcoma, highlighting the potential market opportunity for ozekibart [1]

Core Insights - Inhibrx Biosciences, Inc. announced positive primary results from the ChonDRAgon clinical trial (n=206) evaluating ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma compared to placebo [1] - Based on these results, Inhibrx plans to submit a marketing application for ozekibart for chondrosarcoma to U.S. regulatory authorities by the end of June 2026 [1] - Ozekibart is the first investigational drug to significantly improve progression-free survival (PFS) in chondrosarcoma patients in a randomized controlled trial, addressing a significant unmet medical need [1] Company Developments - The company holds exclusive development and commercialization rights for ozekibart in mainland China, Hong Kong, Macau, and Taiwan through a licensing agreement with its wholly-owned subsidiary, HJB [1] - Inhibrx is also advancing an expanded cohort for ozekibart, assessing its combination with irinotecan for the treatment of Ewing sarcoma and colorectal cancer, with early results showing promising signals [2]

Group 1 - The core point of the news is that Inhibrx Biosciences, Inc. has reported positive primary results from the ChonDRAgon clinical study, which evaluated the efficacy of ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma compared to a placebo [1] - Based on the positive results, Inhibrx plans to submit a marketing application for ozekibart for chondrosarcoma to U.S. regulatory authorities by the end of June 2026 [1] - Ozekibart is the first investigational drug to significantly improve progression-free survival (PFS) in chondrosarcoma patients in a randomized controlled trial, addressing a significant unmet medical need as there are currently no approved systemic treatment options for this disease [1] Group 2 - In addition to the registration clinical trial, Inhibrx is advancing an expanded cohort to evaluate ozekibart in combination with irinotecan for the treatment of Ewing sarcoma and colorectal cancer [2] - Early results from this expanded cohort show encouraging signals, supporting further exploration of ozekibart's potential in these difficult-to-treat tumors with unmet medical needs [2]

本公告由創勝集團醫藥有限公司（「本公司」）自願作出，旨在告知本公司股東及潛 在投資者有關最新業務進展。本公告所用但並無另行界定的詞彙應與本公司日期 為2021年9月14日的招股章程中所賦予該等詞彙的涵義相同。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Transcenta Holding Limited 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） （股份代號：6628） 自願公告 有關創勝集團合作夥伴Inhibrx公佈ozekibart治療軟骨肉瘤的 II期臨床試驗積極結果，計劃於2026年遞交BLA的業績進展 創勝集團醫藥有限公司 本公司董事會（「董事會」）欣然公佈，合作夥伴Inhibrx Biosciences, Inc. （「Inhibrx」，納斯達克代碼：INBX）公佈了註冊性臨床研究ChonDRAgon （n=206）的積極主要結果。該研究評估了ozekibart(INBRX-109)單藥相較安慰劑在 晚期或轉移性、 ...

Core Viewpoint - The analysis of Inhibrx Biosciences (NASDAQ: INBX) reflects a shift from initial optimism at a share price of $15 to a more cautious outlook as the price fluctuated, highlighting the volatility in biotech investments [1]. Company Analysis - Inhibrx Biosciences has been under scrutiny due to its share price movements, which have influenced investor sentiment and expectations [1]. - The author possesses a PhD in biochemistry and extensive experience in analyzing clinical trials and biotech companies, indicating a strong foundation for evaluating the company's potential [1]. Industry Insights - The biotech sector is characterized by significant risks and opportunities, necessitating thorough due diligence to avoid potential pitfalls in investment [1].

Market Overview - U.S. stocks experienced a significant rally, with major indices reaching all-time highs, driven by a softer-than-expected inflation reading that bolstered expectations for a 25 basis point interest rate cut by the Federal Reserve at its upcoming meeting on October 30 [1][4] Inflation Data - The annual headline inflation for September 2025 was reported at 3%, a slight increase from August's 2.9% but below the anticipated 3.1%. Core inflation, excluding food and energy, decreased from 3.1% to 3% year-over-year, indicating a cooler inflation environment [2] Company Performance - Ford Motor Co. emerged as the top-performing large-cap stock, surging 12% following the release of stronger-than-expected third-quarter earnings, marking its best session since 2022 [2] - In the small-cap sector, Inhibrx Biosciences Inc. saw a remarkable 102% increase in stock price after announcing positive trial results for its cancer drug ozekibart [3] Sector Performance - Most sectors within the S&P 500 closed positively, with information technology, communication services, and utilities showing the largest gains. Conversely, energy and materials sectors underperformed, closing lower [3] Index Readings - The CNN Money Fear and Greed Index recorded a reading of 33.1, remaining in the "Fear" zone, which indicates a slight increase from the previous reading of 28.6. This index reflects current market sentiment, with higher fear typically exerting downward pressure on stock prices [5]

Market Overview - U.S. stocks experienced a significant rally, with major indices reaching all-time highs, driven by a softer-than-expected inflation reading that bolstered expectations for a 25 basis point interest rate cut by the Federal Reserve at its upcoming meeting on October 30 [1][4] Inflation Data - The annual headline inflation for September 2025 was reported at 3%, a slight increase from August's 2.9% but below the anticipated 3.1%. Core inflation, excluding food and energy, decreased from 3.1% to 3% year-over-year, indicating a cooler inflation environment [2] Company Performance - Ford Motor Co. emerged as the top-performing large-cap stock, surging 12% following the release of stronger-than-expected third-quarter earnings, marking its best session since 2022 [2] - In the small-cap sector, Inhibrx Biosciences Inc. saw a remarkable 102% increase in stock price after announcing positive trial results for its cancer drug ozekibart [3] Sector Performance - Most sectors within the S&P 500 closed positively, with information technology, communication services, and utilities showing the largest gains. Conversely, energy and materials sectors underperformed, closing lower [3] Index Readings - The CNN Money Fear and Greed Index recorded a reading of 33.1, remaining in the "Fear" zone, which indicates a slight increase from the previous reading of 28.6. This index reflects current market sentiment, with higher fear typically exerting downward pressure on stock prices [5]

Company Highlights - Wellgistics Health, Inc. (NASDAQ:WGRX) experienced a significant price increase of 168.16%, reaching $1.08, driven by its blockchain initiative in prescription drug tracking [1][5] - MaxsMaking Inc. (NASDAQ:MAMK) saw its stock price rise by 148.70% to $7.43, following a successful IPO that raised $6.5 million, indicating strong investor interest in its innovative textile production [1][5] - Inhibrx Biosciences, Inc. (NASDAQ:INBX) reported a stock price surge of 94.43% to $55.13, likely due to positive developments in its clinical trials for a rare bone cancer treatment [2][5] - Genenta Science S.p.A. (NASDAQ:GNTA) experienced a 92.72% increase in stock price to $6.22, attributed to promising clinical trial results and a strategic partnership with ANEMOCYTE [3] Market Dynamics - The significant price movements across these companies reflect diverse investor interest in sectors such as healthcare, biotechnology, and consumer goods, influenced by clinical trial outcomes, strategic partnerships, and innovative product offerings [4]

Core Insights - The article discusses Inhibrx Biosciences, Inc. (NASDAQ: INBX) and its recent developments, particularly following the sale of INBRX-101 to Sanofi [2]. Group 1: Company Overview - Inhibrx Biosciences is highlighted for its continued advancements in the biotech sector despite the recent sale of a key asset [2]. Group 2: Market Position - The author operates a service called Biotech Analysis Central, which provides in-depth analysis of various pharmaceutical companies, indicating a focus on small and mid-cap stocks [2].

Core Insights - The article discusses Inhibrx Biosciences, Inc. (NASDAQ: INBX) and its recent developments, particularly following the sale of INBRX-101 to Sanofi [2]. Company Overview - Inhibrx Biosciences is highlighted for its continued advancement in the biotech sector, indicating a positive trajectory despite the sale of a key asset [2]. Investment Analysis - The author operates a service called Biotech Analysis Central, which provides in-depth analysis of various pharmaceutical companies, including a model portfolio of small and mid-cap stocks [2].